electroCore Inc. has appointed James C. Theofilos to its Board of Directors.

Theofilos has been a senior finance manager within Microsoft Corporation’s Azure and artificial intelligence (AI) division since October 2023. In this role, he is the go-to-market finance lead across Microsoft’s AI Apps & Agents team, which includes all of Microsoft’s AI models, GitHub Copilot, Copilot Studio, and other products that aim to deliver the full value of AI & Agents.

Previously, Theofilos held various finance positions at Microsoft, including the finance lead for Microsoft’s Global Healthcare & Life Sciences Sales team, which included exposure to the health providers, payers, pharmaceutical, and medtech industry verticals. Before that, Theofilos consulted as a group project manager at VICI Properties Inc., a New York City-based publicly traded real estate investment trust primarily engaged in owning and acquiring gaming, hospitality, wellness, entertainment, and leisure destinations.

Theofilos earned a master’s of science degree in finance and a B.S.B.A. in finance from Washington University in Saint Louis.

“I’m honored to have been appointed to the Board of Directors at electroCore,” Theofilos stated. “For nearly two decades, the Theofilos family has deeply believed in the power of the vagus nerve and proudly supported electroCore as both an early investor and founding partner. At Microsoft, I’ve had the privilege of serving as the global finance lead for our healthcare and life sciences business—working alongside some of the world’s largest providers, payers, and pharmaceutical companies to bring innovative, data-driven solutions to market. I look forward to bringing that same lens of strategic growth, AI driven innovation, and operational discipline to help electroCore scale its impact and unlock new opportunities to drive long term shareholder value.”

electroCore Inc. is a commercial stage bioelectronic technology company aiming to improve health and quality of life through innovative non-invasive bioelectronic technologies. The company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.